
REPL Stock Forecast & Price Target
REPL Analyst Ratings
Bulls say
Replimune Group Inc. has seen an increase in the probability of approval for its lead product, RP1, in combination with Opdivo for patients with advanced melanoma, rising to 95%. The company's proprietary in-house manufacturing capabilities enable competitive cost of goods sold, enhancing profitability potential. Additionally, the encouraging clinical data, including an overall response rate of approximately 33% and a median duration of response of 21.6 months, underscores the strong commercial prospects for Replimune's product pipeline, particularly with a potential market entry slated for later this year.
Bears say
Replimune Group Inc. is projected to incur a net loss of $2.99 per share for fiscal 2025, reflecting a worsening financial outlook compared to previous estimates. The company's risks are exacerbated by uncertainties surrounding the efficacy and safety of its lead product candidate, RP1, including challenges in clinical trials and potential regulatory hurdles. Furthermore, there is a concerning possibility of medium- to long-term dilution risk, which could negatively impact shareholder value if development efforts are halted due to safety or efficacy issues.
This aggregate rating is based on analysts' research of Replimune Group Inc and is not a guaranteed prediction by Public.com or investment advice.
REPL Analyst Forecast & Price Prediction
Start investing in REPL
Order type
Buy in
Order amount
Est. shares
0 shares